Forecast

There is no analyst data available for this company.

News Go to news feed

Dentsply Sirona appoints Don Zurbay to the board

Dentsply Sirona has appointed Donald Zurbay to the board of directors effective Jan. 10; he will serve on the audit and finance committee. Zurbay was previously president and CEO of Patterson Companies and brings extensive experience in the dental industry as well as prior CFO experience at St. Jude Medical. The board will expand from ten to eleven members, and the company is also establishing a Growth and Value Creation Committee to oversee the return-to-growth action plan. » More on de.investing.com
Dentsply Sirona: General Counsel Richard C. Rosenzweig steps down and becomes adviser

Dentsply Sirona announced that Richard C. Rosenzweig will relinquish his role as executive vice president for corporate development, general counsel and secretary by mutual agreement and will serve as a special legal advisor through March 4, 2026, for $30,000 per month. Rosenzweig will receive severance and other contractually guaranteed benefits, and will then serve one year as an independent consultant at $20,000 per month; payments are conditioned on a release and compliance with post‑employment obligations. The change comes amid short‑term profitability pressures while Dentsply Sirona makes operational personnel moves (appointment of Aldo M. Denti, retention bonus for Tony Johnson) and analysts reported slightly lowered price targets. » More on de.investing.com
Dentsply Sirona unveils turnaround plan at Baird conference

At the Baird Global Healthcare Conference, Dentsply Sirona announced strategic measures to revive the business, including higher R&D spending (target: 7% of revenue), reallocation of resources and increased sales investments. The company is targeting an operating margin above 19% and a reduction of SG&A to about 30% of revenue, as well as EPS growth of 8–10%, driven mainly by share buybacks. Other measures include ERP implementations, SKU rationalization and retaining the Wellspect business, which contributes roughly 40% of free cash flow. Regional focus is on growth in the US and EMEA and on increasing free cash flow to improve shareholder returns. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Sirona Biochem Co. has already paid €0.0835 in dividends. The last payout was in January 2022.

Financials

In the last year, Sirona Biochem Co. had revenue of €23.69K and net profit of -€1.73M

(EUR)	2023	YoY
Revenue	23.69K	95.25%
Gross profit	-19.6K	104.24%
Net profit	-1.73M	34.46%
EBITDA	-1.59M	39.16%

Fundamentals

Metric	Value
Market capitalization	€1.41M
Number of shares	320.56M
52-week high/low	€0.0184 - €0.0000863
Dividends	No
Beta	-0.07
P/E ratio	-0.70
PEG ratio	0.04
P/B ratio	-0.71
P/S ratio	65.22

Company profile

Sirona Biochem Corp. ist ein Unternehmen für kosmetische Inhaltsstoffe und Arzneimittelforschung, das kosmetische und pharmazeutische Wirkstoffe in Kanada und Frankreich entwickelt und vertreibt. Zu seinen Programmen gehören kosmetische Hautaufheller und Diabetes-Medikamente; weitere Projekte sind die Entwicklung einer Anti-Aging-/Zellschutz-Bibliothek, eines neuartigen Anti-Falten-Wirkstoffs und eines Anti-Viren-Programms. Sirona Biochem Corp. hat eine Forschungskooperation mit dem International Centre for Genetic Engineering and Biotechnology (ICGEB) geschlossen, um eine antivirale Substanzbibliothek zu entwickeln. Das Unternehmen war früher als High Rider Capital Inc. bekannt und änderte im Mai 2009 seinen Namen in Sirona Biochem Corp. Das Unternehmen wurde im Jahr 2006 gegründet und hat seinen Hauptsitz in Vancouver, Kanada.